Hikma Pharmaceuticals’ (HIK) “Buy” Rating Reiterated at Berenberg Bank

Berenberg Bank reiterated their buy rating on shares of Hikma Pharmaceuticals (LON:HIK) in a research report sent to investors on Monday morning, Marketbeat reports. They currently have a GBX 2,560 ($33.20) target price on the stock.

Separately, JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Hikma Pharmaceuticals in a report on Friday, March 7th.

Hikma Pharmaceuticals Stock Performance

HIK opened at GBX 2,072 ($26.87) on Monday. The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27. The firm has a fifty day moving average price of GBX 2,176.60 and a 200 day moving average price of GBX 2,014.14. Hikma Pharmaceuticals has a 1 year low of GBX 1,750 ($22.69) and a 1 year high of GBX 2,360 ($30.61). The stock has a market cap of £5.75 billion, a P/E ratio of 20.33, a P/E/G ratio of 2.38 and a beta of 0.41.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.